PDF(Pubmed)
Abstract：
Anthracyclines are the most fundamental and important treatment of several cancers especially for lymphoma and breast cancer. However, their use is limited by a dose-dependent cardiotoxicity which may emerge early at the initiation of anthracycline administration or several years after termination of the therapy. A full comprehending of the mechanisms of anthracycline-induced cardiotoxicity, which has not been achieved and is currently under the efforts, is critical to the advance of developing effective methods to protect against the cardiotoxicity, as well as to early detect and treat it. Therefore, we review the recent progress of the mechanism underlying anthracycline-induced cardiotoxicity, as well as approaches to monitor and prevent this issue.
摘要：
蒽环类药物是几种癌症的最基本和最重要的治疗方法，尤其是淋巴瘤和乳腺癌。然而,它们的使用受到剂量依赖性心脏毒性的限制,这种心脏毒性可能在蒽环类药物开始时或在治疗终止后数年出现.全面了解蒽环类药物诱导的心脏毒性机制，尚未实现，目前正在努力，对于开发有效的预防心脏毒性的方法至关重要，以及早期发现和治疗它。因此,我们综述了蒽环类药物引起心脏毒性的机制的最新进展，以及监测和预防这一问题的方法。
